Cargando…

Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use?

Suspected acute myocardial infarction is one of the leading causes of admission to emergency departments. In the last decade, biomarkers revolutionized the management of patients with suspected acute coronary syndromes. Besides their pivotal assistance in timely diagnosis, biomarkers provide additio...

Descripción completa

Detalles Bibliográficos
Autores principales: Reinstadler, Sebastian Johannes, Klug, Gert, Feistritzer, Hans-Josef, Metzler, Bernhard, Mair, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415476/
https://www.ncbi.nlm.nih.gov/pubmed/25960596
http://dx.doi.org/10.1155/2015/614145
_version_ 1782369083475361792
author Reinstadler, Sebastian Johannes
Klug, Gert
Feistritzer, Hans-Josef
Metzler, Bernhard
Mair, Johannes
author_facet Reinstadler, Sebastian Johannes
Klug, Gert
Feistritzer, Hans-Josef
Metzler, Bernhard
Mair, Johannes
author_sort Reinstadler, Sebastian Johannes
collection PubMed
description Suspected acute myocardial infarction is one of the leading causes of admission to emergency departments. In the last decade, biomarkers revolutionized the management of patients with suspected acute coronary syndromes. Besides their pivotal assistance in timely diagnosis, biomarkers provide additional information for risk stratification. Cardiac troponins I and T are the most sensitive and specific markers of acute myocardial injury. Nonetheless, in order to overcome the remaining limitations of these markers, novel candidate biomarkers sensitive to early stage of disease are being extensively investigated. Among them, copeptin, a stable peptide derived from the precursor of vasopressin, emerged as a promising biomarker for the evaluation of suspected acute myocardial infarction. In this review, we summarize the currently available evidence for the usefulness of copeptin in the diagnosis and risk stratification of patients with suspected acute myocardial infarction in comparison with routine biomarkers.
format Online
Article
Text
id pubmed-4415476
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-44154762015-05-10 Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use? Reinstadler, Sebastian Johannes Klug, Gert Feistritzer, Hans-Josef Metzler, Bernhard Mair, Johannes Dis Markers Review Article Suspected acute myocardial infarction is one of the leading causes of admission to emergency departments. In the last decade, biomarkers revolutionized the management of patients with suspected acute coronary syndromes. Besides their pivotal assistance in timely diagnosis, biomarkers provide additional information for risk stratification. Cardiac troponins I and T are the most sensitive and specific markers of acute myocardial injury. Nonetheless, in order to overcome the remaining limitations of these markers, novel candidate biomarkers sensitive to early stage of disease are being extensively investigated. Among them, copeptin, a stable peptide derived from the precursor of vasopressin, emerged as a promising biomarker for the evaluation of suspected acute myocardial infarction. In this review, we summarize the currently available evidence for the usefulness of copeptin in the diagnosis and risk stratification of patients with suspected acute myocardial infarction in comparison with routine biomarkers. Hindawi Publishing Corporation 2015 2015-04-16 /pmc/articles/PMC4415476/ /pubmed/25960596 http://dx.doi.org/10.1155/2015/614145 Text en Copyright © 2015 Sebastian Johannes Reinstadler et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Reinstadler, Sebastian Johannes
Klug, Gert
Feistritzer, Hans-Josef
Metzler, Bernhard
Mair, Johannes
Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use?
title Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use?
title_full Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use?
title_fullStr Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use?
title_full_unstemmed Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use?
title_short Copeptin Testing in Acute Myocardial Infarction: Ready for Routine Use?
title_sort copeptin testing in acute myocardial infarction: ready for routine use?
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4415476/
https://www.ncbi.nlm.nih.gov/pubmed/25960596
http://dx.doi.org/10.1155/2015/614145
work_keys_str_mv AT reinstadlersebastianjohannes copeptintestinginacutemyocardialinfarctionreadyforroutineuse
AT kluggert copeptintestinginacutemyocardialinfarctionreadyforroutineuse
AT feistritzerhansjosef copeptintestinginacutemyocardialinfarctionreadyforroutineuse
AT metzlerbernhard copeptintestinginacutemyocardialinfarctionreadyforroutineuse
AT mairjohannes copeptintestinginacutemyocardialinfarctionreadyforroutineuse